Portico Transcatheter Aortic Valve Implantation System
ABBOTT MEDICAL · Decision date Sep 17, 2021
What did the FDA approve?
FDA records P190023 as an original PMA application. The recorded decision is approval, dated Sep 17, 2021.
FDA approval order statement
Approval for the Portico Transcatheter Aortic Valve Implantation System. The device is indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality >= 8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical comorbidities unmeasured by the STS risk calculator).
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 17, 2021
Regulatory record facts
- Identifier
- P190023
- Regulatory pathway
- Premarket approval application
- Applicant
- ABBOTT MEDICAL
- Product code
- NPT
- Decision code
- APPR
- Decision date
- Sep 17, 2021
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Aortic valve, prosthesis, percutaneously delivered.
- Applicant
- Abbott Medical
- Product code
- NPT
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P190023 received
Application receipt date recorded by FDA.
P190023 · FDA decision
APPR
P190023/S033 · Related supplement
Navitor Transcatheter Aortic Valve Implantation System
Timeline entries are records held by MedtechLedger for P190023. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P190023
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Oct 29, 2026 | FDA |
Explore the linked device profile
Other records with product code NPT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Nov 7, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 22, 2026 | FDA | |
Trilogy Transcatheter Heart Valve SystemP250024/S005 | JenaValve Technology, Inc. | PMA supplement | Oct 13, 2026 | FDA |
Trilogy Transcatheter Heart Valve SystemP250024/S006 | JenaValve Technology, Inc. | PMA supplement | Oct 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 177 County Rd. B E., St. Paul, MN, 55117
Sources and methodology
- Original FDA record: P190023
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records